Table 1:
Variable | VATS-LL (n = 45) | VATS-BS (n = 16) | P-Value |
---|---|---|---|
RLL, n (%) | 26 (57.8) | ||
LLL, n (%) | 19 (42.2) | ||
RBS, n (%) | 8 (50) | ||
LBS, n (%) | 8 (50) | ||
Sex male, n (%) | 27 (60) | 12 (75) | <0.99 |
Age, median (IQR) | 68 (11) | 67 (10) | 0.8 |
ASA score, n (%) | 0.556 | ||
1 | 6 (13.3) | 4 (25) | |
2 | 23 (51.1) | 7 (43.8) | |
3 | 16 (35.6) | 5 (31.3) | |
PS, n (%) | 0.621 | ||
0 | 19 (42.2) | 5 (31.3) | |
1 | 19 (42.2) | 7 (43.8) | |
2 | 7 (15.6) | 4 (25) | |
COPD, n (%) | 9 (20) | 4 (25) | 0.675 |
CCI, median (range) | 1 (0–3) | 2 (0–3) | 0.725 |
Smoking history, n (%) | 0.44 | ||
Never smoker | 7 (15.6) | 1 (6.3) | |
Former smoker | 18 (40) | 9 (56.3) | |
Actual smoker | 20 (44.4) | 6 (37.5) | |
NSCLC clinical stage, n (%) | 0.07 | ||
1a | 34 (75.5) | 16 (100) | |
1b | 11 (24.5) | ||
Maximun tumour diameter, median (IQR) | 20 (15) | 18 (9) | 0.35 |
Minimum tumour diameter, median (IQR) | 15 (10) | 13 (5) | 0.48 |
Preoperative PFTs, n (%) | |||
FEV1 l | 1.68 (0.73) | 1.825 (0.58) | 0.9 |
FEV1% | 82.5 (14) | 96 (28.25) | 0.078 |
FVC l | 2.66 (0.86) | 2.63 (1) | 0.49 |
FVC% | 99 (28) | 111.5 (18.4) | 0.3 |
DLCO% | 73.5 (20) | 69.5 (40.75) | 0.3 |
Postoperative PFTs, n (%) | |||
FEV1 l | 1.47 (0.37) | 1.51 (0.65) | 0.26 |
FEV1% | 72.5 (10) | 79.5 (27.5) | 0.016 |
FVC l | 2.03 (0.84) | 2.61 (1.12) | 0.056 |
FVC% | 86 (11) | 96.5 (29) | 0.015 |
DLCO% | 63 (18.5) | 67 (21.5) | 0.22 |
ASA: American Society of Anesthesiologists; CCI: Charlson Comorbidity Index; COPD: chronic obstructive pulmonary disease; DLCO: diffusing capacity for carbon monoxide; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; IQR: interquartile range; LBS: left basal segmentectomy; LLL: left lower lobectomy; NSCLC: non-small-cell lung cancer; PFTs: pulmonary function tests; PS: performance status score; RBS: right basal segmentectomy; RLL: right lower lobectomy; VATS-BS: video-assisted thoracoscopic surgery basal segmentectomy; VATS-LL: video-assisted thoracoscopic surgery lower lobectomy.